Abstract

Type 2 diabetes is a chronic and progressive disease associated with a series of complications, including major
adverse cardiovascular events. As adequate glycemic control has been proven to reduce this risk, sodium-glucose
cotransporter 2 (SGLT2) inhibitors are among the promising medications in managing patients with type
2 diabetes. The current systematic review aimed to explore the SGLT2 inhibitor effects on cardiovascular outcomes.
A filtration procedure was used to remove duplicates and irrelevant publications. The online databases such as PubMed, Google Scholar, and EBSCO were used to perform a literature search, without any date or language restrictions. We used a combination of relevant search terms “diabetes, sodium-glucose cotransporter 2 inhibitors, and cardiovascular." We independently identified publications and systematically screened titles, abstracts, and full texts of the collected publications. Among 200 articles initially selected based on the title and abstract, 197 articles were excluded. Finally, three articles were selected and included in the review. All three studies concerned about the cardiovascular safety of SGLT2 inhibitors and showed that, compared with placebo, empagliflozin, canagliflozin, and dapagliflozin safely lower blood glucose with a reduction in the major adverse cardiovascular events. Across the three trials, empagliflozin, canagliflozin, and dapagliflozin resulted in a consistent class effect on cardiovascular outcomes.

Key words: Cardiovascular events, SGLT2 inhibitor, diabetes.‎